Can reduced cerebral perfusion cause cognitive dysfunction and diffuse EEG slowing without proving hyperviscosity?

Reduced cerebral perfusion is a well-established threat to neuronal metabolism and cognition, particularly relevant in older adults, but diffuse EEG slowing and cognitive symptoms cannot by themselves identify hyperviscosity as the cause.

Clinical and physiologic evidence

• Neurons have minimal energy reserves and require continuous oxygen and glucose delivery for oxidative ATP production, ion-gradient maintenance, and synaptic activity. At sufficiently severe or sustained hypoperfusion, glucose depletion, oxidative failure, depolarization, and ischemic injury may result; impaired function in awake humans has been reported below approximately 22 mL/100 g/min cerebral blood flow.
• In older adults, lower arterial-spin-labeling cerebral perfusion is independently associated with poorer memory, executive function, and global cognition. In longitudinal Rotterdam cohort data, lower perfusion predicted faster cognitive decline and higher dementia risk (hazard ratio 1.31 per 1-SD perfusion decrease).

EEG and mechanistic interpretation

• Hypoperfusion is a biologically credible contributor to diffuse slowing because energy failure disrupts ATP-dependent neuronal and network activity. In probable Alzheimer disease, greater slow-frequency EEG power correlated with lower parietal/hippocampal perfusion and worse MMSE performance.
• However, direct quantitative perfusion-to-EEG causal evidence is limited. Diffuse slowing indicates global cerebral dysfunction/encephalopathy and may parallel impaired attention or consciousness, but it does not specify the underlying mechanism.

Hyperviscosity implications

• Cognitive slowing/confusion and diffuse EEG slowing can occur in hyperviscosity syndrome but are not diagnostic. Similar findings arise with metabolic, toxic, hypoxic-ischemic, infectious, medication-related, structural, and neurodegenerative disorders.
• When hyperviscosity is clinically suspected, supportive findings include visual symptoms, mucosal bleeding, and funduscopic dilated segmented retinal veins (“sausaging”), retinal hemorrhages/exudates, or papilledema. Confirmation relies on serum viscosity measurement; normal values are roughly 1.4–1.8 cP, and symptomatic disease is generally less likely below 4 cP, though clinical context governs interpretation.

Bottom line

• Reduced cerebral perfusion can impair neuronal energy delivery and contribute to cognitive dysfunction; it is a plausible contributor to diffuse EEG slowing. Neither EEG slowing nor cognitive dysfunction establishes hyperviscosity without compatible systemic findings and confirmatory testing.